13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market contains market size and forecasts of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in global, including the following market information:
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) companies in 2021 (%)
The global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Serotype 6B Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) include Pfizer, Minhai Bio, Kexing Bio, Cansino Bio and Lanzhou Biological Preparations Institute, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Segment Percentages, by Type, 2021 (%)
Serotype 6B
7F Serotype
Serotype 9V
14 Serotype
Serotype 18C
Serotype 19A
19F Serotype
23F Serotype
24F Serotype
Other
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Segment Percentages, by Application, 2021 (%)
Infants from 6 Weeks to 15 Months Old
Children Aged 15 Months to 5 Years
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) revenues share in global market, 2021 (%)
Key companies 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales in global market, 2017-2022 (Estimated), (K Units)
Key companies 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Minhai Bio
Kexing Bio
Cansino Bio
Lanzhou Biological Preparations Institute